The Phase I Clinical Study of RS-0139 will advance to the next dose cohort following the positive review of the safety data from the dosing of the first cohort by the Independent Data Monitoring Committee (IDMC).
PDC Therapeutics has passed the first test of its novel nanocarrier technology, getting approval to move up from the initial dose in the phase I trial of lead product RS-0139, which targets a docetaxel payload to tumors expressing the integrin receptor.
The first escalation, to 100 mg/ m², puts RS-0139 ahead dosing-wise of the recommended dose of current formulations of docetaxel at 75 mg/m².
RS-0139’s ongoing clinical study will be presented at the European Society for Medical Oncology (ESMO) 2022 Congress to be held in person on 9-13 September 2022 in Paris – France.
Poster Title: Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)
Date: 12.09.2022
Location: Poster Area, Hall 4
